Heart pump patients get new hope from diabetes drug
NCT ID NCT05278962
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a type of diabetes medicine called SGLT2 inhibitors can help people with severe heart failure who also have a mechanical heart pump (LVAD). Researchers measured changes in heart size, weight, and kidney function over 6 months in 32 adults. The goal was to see if the drug could improve heart health and reduce fluid buildup.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could continuing a common heart drug before surgery save lives?
- Could a natural chemical be the key to safer heart failure treatment?
- Can a Breathing-Synchronized pacemaker boost heart function after bypass?
- Can 3D heart scans outperform standard ultrasound in predicting risk?
- Iron infusions put to the test for heart failure stamina
- Zapping lung nerves could ease heart Failure-Related high blood pressure